Introduction {#S0001}
============

Large-cell lung cancer (LCLC) is the third-most common subtype of non-small-cell lung carcinoma (NSCLC) after adenocarcinoma and squamous-cell carcinoma, representing 2%--3% of NSCLCs.[@CIT0001] LCLCs comprise many different subtypes, lack morphological features, and are poorly differentiated. In order to achieve accurate distinction of the histological subtypes of LCLC, cases were regrouped using the 2015 World Health Organization (WHO) classification of lung tumors, characterized by a lacking of histological features and immunomarkers for neuroendocrine, squamous, or glandular differentiation.[@CIT0002] Eventually, there has been a decrease in the number of confirmed LCLC cases. In addition, in comparison to other NSCLC subgroups, LCLC showed an inferior survival, independently from the type of chemotherapy.[@CIT0003]

The combination of different therapeutic modalities in the treatment of lung cancer has undergone tremendous progress.[@CIT0004] Tyrosine kinase--inhibitor therapies targeting *EGFR* mutations and *ALK* gene rearrangements have strikingly improved patients' quality of life and survival. The progression of NSCLCs may be primarily driven by the MET pathway, which mainly includes a MET exon 14--skipping mutation and de novo MET amplification with a reported prevalence of 1%--5%.[@CIT0005] More recent studes have focused on *MET* mutations and amplifications for favorable clinical responses to METinhibitor therapy.[@CIT0006],[@CIT0007] In addition, antibodies targeting PD1 have shown unprecedented durable clinical responses in lung cancer.[@CIT0008],[@CIT0009] Extensive efforts have been made to identify predictive markers for anti-PD1 therapies, such as expression of PDL1 by tumor cells,[@CIT0008],[@CIT0009] tumor mutational burden,[@CIT0010] and DNA mismatch--repair deficiency.[@CIT0011] Moreover, PD1 antibodies were approved as first-line therapy in NSCLC patients with elevated PDL1 expression on tumor-cell surfaces.[@CIT0012] LCLC remains unclear with regard to genetic alterations, and there have been few reports based on PDL1 expression and its prognostic relevance.[@CIT0004],[@CIT0005]

In this study, we reclassified LCLCs based on the 2015 WHO classification of tumors, and investigated the overall rate of targetable alterations in LCLC using routine clinical laboratory technologies to evaluate probable therapeutic options and their potential prognostic value.

Methods {#S0002}
=======

Study patients {#S0002-S2001}
--------------

Cases who had undergone surgical resection between January 2005 and April 2017 were retrieved from the pathological and diagnostic database of Sun Yat-sen University Cancer Center using the keywords "lung" and "large cell carcinoma". Data on clinical information, sex, age, smoking status, and TNM stage (eighth Union for International Cancer Control TNM staging system for NSCLC) were recorded. Smoking status was categorized as ever or never (\<100 lifetime cigarettes). Clinical follow-up information was obtained from the medical records of inpatient or outpatient visits, as well as telephone interviews until September 10, 2018. Overall survival (OS) was calculated from the time of primary surgical resection to patient death from any cause or last contact. The study was approved by the Research Ethics Committee of the Sun Yat-sen University Cancer Center (B2016-069-01).

Immunohistochemistry {#S0002-S2002}
--------------------

Immunohistochemistry (IHC) experiments in each case were conducted using the BenchMark XT automated immunostainer (Ventana, Tucson, AZ, USA) with antibody chromogranin A (CgA; clone LK2H10; Ventana), Syn (clone SP11, 1:50; Geneentech), CD56 (clone 123C3D5; Ventana), TTF1 (clone SP141; Ventana), p63 (clone 4A4 recognizing all p63 gene isoforms, 1:200; Geneentech Company Limited), napsin A (polyclonal; Ventana), p40 (rabbit polyclonal, 1:100; Maixin), and CK5/6 (clone MX040; Maixin). The determination of PDL1 expression was performed using the rabbit monoclonal anti-PDL1 antibody (E1L3N, dilution 1:200; Cell Signaling Technology, Danvers, MA, USA). Negative and positive controls were included in each staining batch. For each marker, the percentage and intensity of positive cells were recorded. PDL1 expression in tumor cells and tumor-infiltrating lymphocytes (TILs) was positive when moderate--strong membrane staining was observed in ≥5% of the tumor cells and ≥1% of TILs, respectively.[@CIT0013] A tumor was considered positive for other diagnostic markers when moderate--strong staining was observed in ≥10% of the tumor cells. IHC analysis was independently performed by two pathologists (JBL and YFF). When disagreement arose, a third pathologist (FW) reconfirmed.

Identification of LCLC {#S0002-S2003}
----------------------

All original H&E and IHC staining slides were reviewed by two experienced pathologists (JBL and YFF), and cases with neuroendocrine morphological features were evaluated for IHC staining with the neuroendocrine markers CD56, CgA, and Syn. Cases without neuroendocrine features were subsequently analyzed for IHC staining with TTF1, napsin A, p40, and CK5/6 to identify glandular or squamous differentiation. In all cases with negative immunomarkers, alcian blue--periodic acid Schiff staining was performed to rule out solid adenocarcinoma with mucin production. Marker-null NSCLC cases reclassified as LCLC according to the 2015 WHO guidelines were further detected for genetic variation.[@CIT0002] Representative images of each diagnostic category are provided in [Figure S1](#SF0001).

DNA extraction and genetic variations {#S0002-S2004}
-------------------------------------

AS QIAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany) was used to extract DNA from paraffin-embedded tissue samples, and the presence of tumor cells (\>70%) was obtained by trimming the normal and necrotic tissues. Genetic analyses of *EGFR*, *KRAS*, and *BRAF* were performed using the OncoCarta Panel[@CIT0014] (version 1.0; Sequenom, San Diego, CA, USA). Mutation data were analyzed using MassArray Typer software version 4.0 (Sequenom). *MET* skipping mutation was detected by direct sequencing[@CIT0006] using a PTC-200PCR (Bio-Rad, Hercules, CA, USA) with the forward primer 5'-CTTTGTACGTCTCATGTTAT-3' and reverse primer 5'-CTCCTAGCGACCTAAC-3'. PCR products were purified and labeled using a BigDye Terminator 3.1 cycle-sequencing kit (Applied Biosystems, Foster City, CA), followed by sequencing in an ABI 3500XL Genetic Analyzer (Applied Biosystems).[@CIT0015]

Fluorescence in situ hybridization (FISH) {#S0002-S2005}
-----------------------------------------

*MET* gene copy number per cell was investigated with fluorescence in situ hybridization (FISH) using an MET/chromosome 7 centromere probe (Kreatech Diagnostics, Amsterdam, Netherlands). *ALK* and *ROS1* genes were examined separately with a LSI ALK dual-color, break-apart rearrangement probe and LSI ROS1 dual-color, break-apart rearrangement probe (Vysis; Abbott Laboratories, Chicago, IL, USA). FISH analysis was performed independently by two pathologists (XA and QS). Rearrangement-positive cells were defined as described previously.[@CIT0016],[@CIT0017] Copy number or apart signals per cell were counted in 100 nonoverlapping tumor-cell nuclei. FISH signals were assessed under microscopy (BX51 TRF; Olympus, Tokyo, Japan) equipped with a triple-pass filter (DAPI/green/orange; Vysis). Tumors with five or more *MET* signals per cell were classified as FISH^+^ according to the Capuzzo scoring system, including *MET* polysomy with *MET* signals five orfewer and fewer than ten and MET amplification characterized by tumor cells with MET:CEP7 ratio greater than or equal to two and ten signals per cell in \>10% tumor cells or tight gene clusters ([Figure S2](#SF0002)).[@CIT0006],[@CIT0018],[@CIT0019]Figure S2Fluorescent in situ hybridization for *MET* gene (orange) and centromere 7 (green).**Notes:** Negative (**A**); *MET* polysomy (**B**); *MET* amplification (**C**); tight gene clusters (**D**). Magnification 1,000×.

Statistical analysis {#S0002-S2006}
--------------------

Differences in distributions of LCLC patients' characteristics between groups were evaluated by *χ*^2^ or Fisher's test. Cases with second primary cancer were excluded from survival analysis. The Kaplan--Meier method was used to estimate 5-year OS with 95% CIs of LCLC patients in different groups, and two-sided log-rank tests were applied to determine statistical significance. Each genetic and clinical feature is the estimated regression coefficient of a prognostic factor in multivariate Cox regression analysis. All statistical analyses were performed using SPSS 23.0, and *P*\<0.05 was considered statistically significant.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

The records of 184 lung cancer patients were retrieved, and based on the study requirements ([Figure 1](#F0001){ref-type="fig"}) 54 patients eventually diagnosed with LCLC were found eligible. The clinicopathological characteristics of these LCLC patients are summarized in [Table 1](#T0001){ref-type="table"}. The median age was 58 years (range 33--74 years). The majority of patients were male (92.6%, 50 of 54) and smokers (79.6%, 43 of 54). A total of 48 patients had received lobectomy, three pneumonectomy, and three wedge resection. Nineteen patients (35.2%) were diagnosed as stage I, 16 (29.6%) as stage II, 15 (27.8%) as stage III, and four (7.4%) as stage IV. Fourteen patients received platinum-based adjuvant chemotherapy, two patients radiotherapy, one radiochemotherapy, and three neoadjuvant chemotherapy (one received radiochemotherapy after operation) during the course of the surgical treatment. Additionally, one patient received gefitinib as subsequent treatment, due to a recurrence after resection. The median follow-up was 21.8 months (range 1--147.7 months), and 25 patients (46.3%) died of tumors.Table 1.Baseline characteristics of 54 LCLC patientsPatientsn%**Age, years**Median58Range33--74**Sex**Male5092.6Female47.4**Smoking status**Never-smoker1120.3Smoker4379.6**Surgical treatment**Wedge resection35.6Lobectomy4888.9Pneumonectomy35.6**Location**Central1425.9Peripheral4074.1**TNM stage**I1935.2II1629.6III1527.8IV47.4[^1] Figure 1Flowchart illustrating LCLC patient enrollment.**Abbreviations:** SCC, squamous-cell carcinoma; LCNEC, large-cell neuroendocrine carcinoma; AD, adenocarcinoma; LCLC, large-cell lung carcinoma.

Molecular profiling {#S0003-S2002}
-------------------

Nine patients (16.7%, nine of 54) harbored *KRAS* mutations in codon 12 (three G12V, three G12D, two G12C, and one G12A), which were significantly associated with larger tumors (*P*=0.008, [Table 2](#T0002){ref-type="table"}) and advanced stage (*P*=0.019, [Table 2](#T0002){ref-type="table"}). Three female patients had an *EGFR* mutation (two L858R and one E746-A750del), one a *BRAF*^D594N^ mutation, and there were no cases of *ALK*, *ROS1*, or *RET* rearrangement or *MET* exon 14-skipping mutations. Ten cases were classified as *MET* FISH^+^, with two distinct patterns: amplification (n=5) and polysomy (n=5). In addition, two cases were identified with *MET* polysomy (signals 5.7 and 6.2) coexisting with *KRAS* mutation. However, the *MET* FISH^+^ had no association with clinicopathological features. PDL1 expression in tumor cells was positive in 24 patients (44.4%, 24 of 54), of which were high expression, with ≥50% of tumor cells with moderate--strong staining (27.8%, 15 of 54). PDL1 expression in TILs was positive in 16 patients (TIL^+^, 29.6%). The representative images of PDL1 expression are shown in [Figure 2](#F0002){ref-type="fig"}. Positive PDL1 expression in both tumor cells and TILs occurred more frequently in patients with stage IV (*P*=0.016 and 0.039, respectively; [Table 2](#T0002){ref-type="table"}), but showed no significant relationship with other clinicopathological features.Table 2.Correlation of clinical characteristcs of 54 LCLC patients with *MET* FISH status, *KRAS* mutations, and PDL1 expression*MET*KRASPDL1SubtypesFISH^--^FISH^+^*P*Wild-typeMutation*P*Tumor cell^--^Tumor cell^+^*P*TIL^--^TIL^+^*P***Age, years**≤5720 (74.1)7 (25.9)0.29323 (85.2)4 (14.8)115 (55.6)12 (44.4)118 (66.7)9 (33.3)0.766\>5724 (88.9)3 (11.1)22 (81.5)5 (18.5)15 (55.6)12 (44.4)20 (74.1)7 (25.9)**Sex**Male40 (80.0)10 (20.0)0.42941 (82.0)9 (18.0)128 (56.0)22 (44.0)135 (70.0)15 (30.0)1Famale4 (100.0)04 (100.0)02 (50.0)2 (50.0)3 (75.0)1 (25.0)**Smoking status**Smoker34 (79.1)9 (20.9)0.66736 (83.7)7 (16.3)123 (53.5)20 (46.5)0.73630 (69.8)13 (30.2)1Never-smoker10 (90.9)1 (9.1)9 (81.8)2 (18.2)7 (63.6)4 (36.4)8 (72.7)3 (27.3)**Location**Central3 (92.9)1 (7.1)0.25513 (92.9)1 (7.1)0.41810 (71.4)4 (28.6)0.21811 (78.6)3 (21.4)0.515Peripheral31 (77.5)9 (22.5)32 (80.0)8 (20.0)20 (50.0)20 (50.0)27 (67.5)13 (32.5)**Tumor size**T19 (90.0)1 (10.0)0.8969 (90.0)1 (10.0)0.0088 (80.0)2 (20.0)0.0998 (80.0)2 (20.0)0.776T221 (77.8)6 (22.2)26 (96.3)1 (3.7)16 (59.3)11 (40.7)18 (66.7)9 (33.3)T313 (81.3)3 (18.7)10 (62.5)6 (37.5)6 (37.5)10 (62.5)12 (75.0)4 (25.0)**Lymph-node status**N-24 (77.4)7 (22.6)0.49425 (80.6)6 (19.4)0.44517 (54.8)14 (45.2)0.78625 (80.6)6 (19.4)0.124N+19 (86.4)3 (13.6)20 (90.9)2 (9.1)13 (59.1)9 (40.9)13 (59.1)9 (40.1)**Stage**I16 (84.2)3 (15.8)0.30819 (100.0)00.01513 (68.4)6 (31.6)0.01617 (89.5)2 (10.5)0.039II11 (68.8)5 (31.3)10 (62.5)6 (37.5)6 (37.5)10 (62.5)11 (68.8)5 (31.2)III14 (93.3)1 (6.7)13 (86.7)2 (13.3)11 (73.3)4 (26.7)9 (60.0)6 (40.0)IV3 (75.0)1 (25.0)3 (75.0)1 (25.0)04 (100.0)1 (25.0)3 (75.0)[^2] Figure 2Representative IHC staining of for PDL1 expression shown in LCLC tissue.**Notes:** Membranous positive staining of PDL1 in tumor cells (**A**) and TILs (**B**). Membranous positive and negative staining of PDL1 in tumor cells (**C**) and TILs (**D**). Original magnification ×20.**Abbreviations:** IHC, immunohistochemistry; LCLC, large-cell lung carcinoma; TILs, tumor-infiltrating lymphocytes.

LCLC patient survival {#S0003-S2003}
---------------------

Patients with a *KRAS* mutation had lower OS than those with wild-type *KRAS* (25.4% vs 47.8%, *P*=0.028; [Figure 3A](#F0003){ref-type="fig"}). There was no significant difference in OS between patients based on MET FISH status (46.7% vs 36.0%, *P*=0.635; [Figure 3B](#F0003){ref-type="fig"}). Positive PDL1 status in tumor cells trended marginally toward poorer OS (56.2% vs 34.0%, *P*=0.085; [Figure 3C](#F0003){ref-type="fig"}). PDL1 expression in TILs showed no significance on 5-year OS (53.0% vs 40.6%, *P*=0.314; [Figure 3D](#F0003){ref-type="fig"}). Further, patients with negative PDL1 staining in tumor cells, but positive expression in TILs (n=6) showed significantly favorable OS compared to those with PDL1-positive tumor cells but negative TILs (n=14, 62.5% vs 20.6%, *P*=0.044; [Figure 3E](#F0003){ref-type="fig"}). There were no significant differences in OS between patients with positive PDL1 in both compartments (n=10) those with both negative PDL1 (n=24, 30% vs 25%; *P*=0.720). When clinical and genetic variables were considered as prognostic factors, univariate analysis revealed that only *KRAS* mutation was an independent risk factor for poor OS (HR 2.72, 95% CI 1.07--6.91, *P*=0.035; [Table 3](#T0003){ref-type="table"}).Table 3.Univariate associations of clinicopathological characteristics, and status of EGFR, KRAS and PDL1 expression with OS in the 54 LCLC patientsUnivariableVariablesSubtypesHR (95% CI)*P*SexFemale vs male0.93 (0.22--3.96)0.924Age, years\>57 vs ≤571.04 (0.48--2.28)0.921Smoking statusNever-smoker vs smoker0.37 (0.11--1.25)0.109Tumor sizeT3 vs T1, T21.04 (0.43--2.51)0.932Lymph-node metastasisLN^+^ vs LN^--^1.71 (0.78--3.75)0.181StageAdvanced vs early1.59 (0.72--3.49)0.254LocationCentral vs peripheral0.81 (0.32--2.03)0.654EGFR mutationmutation vs wild-type2.46 (0.73--8.30)0.148KRAS mutationMutation vs wild-type2.72 (1.07--6.91)0.035*MET*FISHFISH^+^ vs FISH^--^1.25 (0.50--3.13)0.635PDL1 expression in tumor cellsPositive vs negative2.00 (0.89--4.46)0.091PDL1 expression in TILsPositive vs negative0.64 (0.26--1.54)0.318[^3] Figure 3OS analysis in LCLC patients with alterations in different genes.**Notes:** (**A**, **B**) Kaplan--Meier model of OS according to *KRAS* and *MET* status, respectively. (**C, D**) Kaplan--Meier model for OS in patients with different PDL1 expression in tumor cells and TILs, respectively. (**E**) Kaplan--Meier model of OS among patients with different PDL1 expression in both tumor cells and TILs.

Discussion {#S0004}
==========

Diagnostic terminology on LCLC has been inconsistently applied in clinics, based only on morphology and insufficient IHC markers. This study revealed that *KRAS* mutations and PDL1 expression were related to patient survival, indicating that *KRAS* and PDL1 might be therapeutic targets for LCLC patients.

The oncological efficacy of genes in LCLC is generally limited; therefore, LCLC was incorporated in the adenocarcinoma category for treatment and molecular testing in current recommendations in the National Comprehensive Cancer Network guidelines for NSCLC (version 3.2018). *EGFR* mutations and *ALK* rearrangement are the key predictive molecular variables for targeted therapy in lung cancer, but their occurrence in LCLC is comparatively rare. One explanation could be that the majority of patients with LCLC are male and smokers. Several studies have reported the mutational landscape of LCLC in comparison with adenocarcinoma or squamous-cell carcinoma. Rekhtman et al found five *KRAS* codon 12 missense mutations and one *BRAF*^V600E^ mutation in a set of 20 marker-null large-cell carcinomas (immunomarkers negative for TTF1 and p40).[@CIT0020] Karlsson et al found one each of *BRAF*^Q456K^ and *MET*^T1010I^ in a set of 12 large-cell carcinomas (immunomarkers negative for TTF1, p40, napsin A, and CK5).[@CIT0021] Driver et al found two *BRAF*^D594N^ and one *KRAS*^G12C^ in two regrouped large-cell carcinomas using next-generation sequencing covering 50 genes.[@CIT0022] Karlsson et al found only one each of *BRAF*^Q546K^ and *PTEN*^F257L^ in a set of ten reclassified large-cell carcinomas through gene expression--profiling analysis.[@CIT0023] In the present study, *KRAS* mutations (16.7%) were identified as showing significant correlation with worsened prognosis, which was consistent with previous studies. *KRAS* activation is the most common oncogenic alteration in LCLC, but remains controversial as a prognostic marker.[@CIT0024] However, most studies have shown that *KRAS* mutation was a negative prognostic marker in NSCLC.[@CIT0025],[@CIT0026]

*MET* gene amplification has been identified as one of the mechanisms of acquired resistance to anti-EGFR therapy in patients with activating *EGFR* mutations.[@CIT0027] Nevertheless, de novo *MET* amplification is rare, ranging 1%--5% depending on the assay and positivity cut point used, and has been associated with poor outcomes in NSCLC.[@CIT0028] Only this high-level amplification category and *MET* exon 14 alterations are likely to be predictive of response to *MET* inhibition, such as with crizotinib.[@CIT0029] In our study, *MET* FISH^+^ was determined in ten patients (11.1%), including five cases (9.3%) with true gene amplification, using the Cappuzzo scoring system. Although no *MET* exon 14 mutation was identified in this study, *MET* amplification as a relatively high-frequency alteration was found in LCLC compared with other NSCLC, suggesting these patients may benefit from MET inhibitors.

Various issues and clinical trials of PD1 blockade have been reported regarding tumor-cell PDL1 expression as a putative biomarker of therapeutic response. Also, TILs indicating a "T cell--inflamed phenotype" have been assessed for their association with anti-PD(L)1 therapy.[@CIT0030] However, most research has concerned PDL1 expression in adenocarcinoma, squamous-cell carcinoma, small-cell carcinoma, or large-cell neuroendocrine carcinoma, with little on large-cell carcinoma. We used the E1L3N antibody and observed 44.4% and 27.8% positive PDL1 expression on tumor cells and TILs, respectively. Although IHC is a good method for assessment of PDL1 expression, different staining assays may cause differences in PDL1 expression.[@CIT0031],[@CIT0032] The E1L3N assay has been reported to be less sensitive, especially for lower-intensity staining levels, than the SP263 assay. To our knowledge, this is the first integrated report about PDL1 expression of LCLC. Elevated PDL1 in TILs indicated that the PD1--PDL1 pathway might be activated in patients with negative PDL1 expression in tumor cells, and this subgroup with PDL1 expression in solitary TILs obtained an optimal outcome. This found was similar with large-cell neuroendocrine carcinoma.[@CIT0033] In addition, combining PDL1 expression in tumor cells and TILs would help greatly in classifying cancers and selecting patients for anti-PD(L)1 monotherapy or combination therapies.[@CIT0034] Herbst et al found that PDL1 expression on TILs could predict favorable responses to atezolizumab better than PDL1 expression on tumor cells.[@CIT0013]

The present study covered a relatively large number of cases with LCLC. However, there are also some limitations that may be of concern. Firstly, it could not entirely uncover the mutational landscape of LCLC using routine clinical technology. Next-generation sequencing technology should be performed to obtain comprehensive knowledge about tumor mutational burden and the tumor microenvironment in further investigations. Secondly, most samples of the advanced cases obtained from small biopsies were excluded, since LCLC can be diagnosed onlyin a surgically resected tumor according to the WHO 2015 criteria. As such, the survival analysis may be biased to a large extent.

Conclusion {#S0005}
==========

We detected main driver-gene alterations and PDL1 status in the 54 patients with marker-null LCLC according to the 2015 WHO classification. *KRAS* mutation was found to be associated with higher stage of disease and poorer OS, and on the other hand negative PDL1 expression in tumor cells but positive expression in TILs were related with a favorable outcome. Improved genetic understanding can help LCLC patients evaluate probable targeted and immunotherapy regimens.
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Figure S1Representative images of each diagnostic category for LCLC.**Notes:** According to the 2015 World Health Organization classification of tumors, the morphological features of LCLC were considered through IHC: (**A**) H&E staining of LCLC; (**B**) CK staining positive observed in tumors characterized by epithelial origin; (**C--E**) negative IHC staining with neuroendocrine markers, CD56, CgA, and Syn; (**F--J**) negative IHC staining with TTF1, napsin A, p40, CK5/6, and p63 to identify glandular or squamous differentiation.**Abbreviations:** LCLC, large-cell lung carcinoma; IHC, immunohistochemistry.
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